Fundraising Fox

CardioMech

Trondheim, NO · Incorporated in Norway · 1 known investors

cardiomech.com ↗

CardioMech develops a transcatheter mitral valve repair system (MVRS) that delivers artificial chords via a transfemoral, transseptal catheter approach to treat degenerative mitral regurgitation on a beating heart. The device targets heart disease patients as a less-invasive alternative to open-heart surgery and is currently for investigational use only.

BiotechHealthtechMedical Devices

Founders & leadership

RN
Richard NehmNamed on SEC filing
JH
Jan HabrekkeNamed on SEC filing
VJ
Vic, Jr. BertrandNamed on SEC filing
JB
Jacob BergslandNamed on SEC filing
NH
Nikolai HiorthNamed on SEC filing
MN
Mark NovotnyNamed on SEC filing

Board

FEFlorian Eckhardt
Florian EckhardtBoard directorSenior Advisor at Hadean Ventures

Investors · 1

Hadean VenturesOslo

Reported raises · per SEC filings

Form D private placements

$57.7M disclosed across 7 rounds · 2019–2025

▶$17.6MraisedApr 2025 · 58 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Richard NehmExecutive Officer, Director
  • Florian EckhardtDirector
  • Jan HabrekkeDirector
  • Vic, Jr. BertrandDirector
Offering amount
$17.6M
Amount sold
$17.6M
Minimum investment
$10K
First sale
Apr 2025
Incorporated
Other, Norway
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12.7MraisedDec 2023 · 100 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Richard NehmExecutive Officer, Director
  • Jacob BergslandDirector
  • Vic, Jr. BertrandDirector
Offering amount
$12.7M
Amount sold
$12.7M
Minimum investment
$5K
First sale
Dec 2023
Incorporated
Other, Norway
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.5MraisedFeb 2023 · 38 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Vic Bertrand, Jr.Director
  • Florian EckhardtDirector
  • Mark NovotnyDirector
  • Richard NehmExecutive Officer, Director
Offering amount
$4.5M
Amount sold
$4.5M
Minimum investment
$10K
First sale
Feb 2023
Incorporated
Other, Norway
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.2MraisedApr 2022 · 34 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Vic, Jr. BertrandDirector
  • Florian EckhardtDirector
  • Mark NovotnyDirector
  • Richard NehmExecutive Officer, Director
Offering amount
$6.2M
Amount sold
$6.2M
Minimum investment
$5K
First sale
Apr 2022
Incorporated
Other, Norway
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9.2MraisedAug 2020 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark NovotnyDirector
  • Richard NehmExecutive Officer, Director
  • Vic, Jr. BertrandDirector
  • Florian EckhardtDirector
Offering amount
$9.2M
Amount sold
$9.2M
Minimum investment
$733.3K
First sale
Aug 2020
Incorporated
Other, Norway
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedAug 2019 · 54 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Richard NehmExecutive Officer, Director
  • Jacob BergslandExecutive Officer, Director
  • Frederik Justin Gabriel GroenewegenDirector
  • Vic Joseph BertrandDirector
  • Nikolai HiorthExecutive Officer
  • Mark NovotnyDirector
Offering amount
$5M
Amount sold
$5M
Minimum investment
$10K
Proceeds to insiders
$400K
First sale
Aug 2019
Incorporated
Other, Norway
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.5MraisedFeb 2019 · 39 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jacob BergslandExecutive Officer, Director
  • Richard NehmExecutive Officer, Director
  • Nikolai HiorthExecutive Officer
  • Mark NovotnyDirector
Offering amount
$2.5M
Amount sold
$2.5M
Minimum investment
$15K
Proceeds to insiders
$170K
First sale
Feb 2019
Incorporated
Other, Norway
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 8

by search overlap
Rf Surgical6 shared keywordsMedtronic develops healthcare technology, including pulsed field ablation systems used to treat atrial fibrillation (AFib). The company serves clinicians and healthcare providers in the medical device and cardiac care field.
Cardiovalve5 shared keywordsCardiovalve develops a transcatheter valve replacement system designed to fit both mitral and tricuspid anatomies via transfemoral delivery, avoiding open heart surgery. The device targets structural heart disease and is currently restricted to research use.
Massdevice5 shared keywordsMassDevice is a news and media outlet covering the medical device industry, publishing articles, special reports, and white papers on medtech companies, products, and regulatory topics such as FDA 510(k) submissions. It serves medical device professionals with industry news and analysis.
Corcym4 shared keywordsCorcym is a global medical device company focused on structural heart disease, developing heart valve prostheses and repair devices such as sutureless aortic heart valves. It serves healthcare professionals and cardiac patients, and offers professional education programs in partnership with scientific societies.
4C Medical Technologies4 shared keywords4C Medical develops AltaValve, a supra-annular transcatheter mitral valve replacement (TMVR) system for treating mitral regurgitation. The atrial-anchored device is designed to preserve cardiac structures and treat a broader patient population; it is currently an investigational device.
Merit Medical4 shared keywordsMerit Medical Systems designs, develops, manufactures and markets medical devices for interventional and diagnostic procedures. The company serves healthcare providers and clinical practitioners in the medical device industry.
Abbott3 shared keywordsAbbott's Lingo Glucose System is a continuous glucose monitoring device for non-insulin users aged 18+, designed to track glucose levels and support metabolic health decisions.
Micro Interventional Devices3 shared keywordsMicro Interventional Devices designs and manufactures medical devices for transcatheter cardiac repair procedures, enabling minimally invasive alternatives to open-heart surgery. The company initially focuses on transcatheter mitral and tricuspid valve repair solutions.

Companies competing with CardioMech for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does CardioMech do?
CardioMech develops a transcatheter mitral valve repair system (MVRS) that delivers artificial chords via a transfemoral, transseptal catheter approach to treat degenerative mitral regurgitation on a beating heart. The device targets heart disease patients as a less-invasive alternative to open-heart surgery and is currently for investigational use only.
Who are CardioMech's investors?
CardioMech's investors include Hadean Ventures.
How much funding has CardioMech raised?
CardioMech has disclosed $57.7M raised across 7 rounds.
Where is CardioMech headquartered?
CardioMech is headquartered in Trondheim, NO.